MIST Stock Analysis: Buy, Sell, or Hold?
MIST - Milestone Pharmaceuticals Inc. Common Shares
$1.91
0.02 (1.06%)
▲
5d:
-3.54%
30d:
-2.55%
90d:
+3.8%
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 12, 2026
Smart Money Accumulation
MIST is down 3.5% this week, but smart money is accumulating calls. Top strike: $2 2026-03-20 with 4,515 OI. Call ratio: 91% View Scanner →
Strength: 5.9/10
Get Alerted When MIST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
6 traders called MIST this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MIST shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: MIST shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: MIST is currently trading at $1.91, which is considered oversold relative to its 30-day fair value range of $1.95 to $2.08.
Technical Outlook: Technically, MIST is showing sideways momentum. The price is currently testing key support at $1.86. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MIST has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.60 (+245.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MIST is showing sideways momentum. The price is currently testing key support at $1.86. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MIST has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.60 (+245.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.95 -
$2.08
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 245.5% below Wall St target ($6.60)
Fair Price Analysis
30-Day Fair Range
$1.95 -
$2.08
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.86
Resistance Level
$2.11
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
-3.20
Wall Street Target
$6.60
(+245.5%)
Revenue Growth (YoY)
-100.0%
Last updated: February 01, 2026 11:21 PM ET
Data refreshes hourly during market hours. Next update: 12:21 AM
Data refreshes hourly during market hours. Next update: 12:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MIST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$847 | 52 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$213 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 63 BUY |
